Content Search Navigation Sitemap News & insights Search all news & insights Latest news all topics Sustainability Financial Operating News all companies Syncona all Commercial companies companies Autolus Therapeutics all Late-stage clinical companies companies Beacon Therapeutics Spur Therapeutics all Clinical companies companies iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics all Pre-clinical companies companies Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO Clinical companies iOnctura Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 Clinical companies Resolution Therapeutics Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress Late-stage clinical companies Spur Therapeutics Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 Clinical companies Resolution Therapeutics Yellowstone Biosciences Appoints James (“Jim”) MacDonald as Chief Executive Officer Pre-clinical companies Yellowstone Biosciences Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer Clinical companies Resolution Therapeutics Latest insights & articles all topics Sustainability World class leadership Life Science industry Foundation case study Found, build, fund Syncona platform all companies Syncona all Commercial companies companies Autolus Therapeutics all Late-stage clinical companies companies Beacon Therapeutics Spur Therapeutics all Clinical companies companies iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics all Pre-clinical companies companies Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics A new partner: Horatio’s Garden Syncona Supporting UK life science Syncona Market Review: Fundamentals are robust, despite uncertainty Syncona Fellowship Spotlight Series: Ellis Kelly Syncona Introducing Slingshot Therapeutics Pre-clinical companies Slingshot Therapeutics Creating Yellowstone – Syncona’s launch team in action Syncona platform Pre-clinical companies Yellowstone Biosciences Latest publications & presentations all companies Syncona all Commercial companies companies Autolus Therapeutics all Late-stage clinical companies companies Beacon Therapeutics Spur Therapeutics all Clinical companies companies iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics all Pre-clinical companies companies Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Spur Corporate Presentation - February 2025 Autolus Corporate Presentation - January 2025 Syncona - Half Year 2024 Presentation Syncona Investor Webinar: Beacon Therapeutics Spur Corporate Presentation - October 2024 Autolus Corporate Presentation - September 2024 About View this section View this section Who we are NAV Growth Framework View this section View this section Who we are NAV Growth Framework Our people View this section View this section Board of Directors View this section View this section Board of Directors Portfolio View this section View this section Commercial companies Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Pre-clinical companies Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Previous portfolio companies Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics View this section View this section Commercial companies Overview Autolus Therapeutics Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Pre-clinical companies Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Previous portfolio companies Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics Sustainability View this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies View this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overview Regulatory publications Shareholder documents FAQs View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overview Regulatory publications Shareholder documents Overview Regulatory publications Shareholder documents FAQs Contact Search